NCT02206204View on ClinicalTrials.gov

Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
CardiodynamicsSafetyTolerabilityPharmacokinetics
Interventions
DRUG

selexipag

DRUG

placebo for selexipag

DRUG

moxifloxacin

DRUG

moxifloxacin-matching placebo

Trial Locations (1)

47710

Covance Clinical Research Unit, Evansville

Sponsors

Lead Sponsor

Actelion
All Listed Sponsors
lead

Actelion

INDUSTRY

NCT02206204 - Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects | Biotech Hunter | Biotech Hunter